

# Badar M Mian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3208868/publications.pdf>

Version: 2024-02-01

24  
papers

510  
citations

1307366

7  
h-index

887953

17  
g-index

27  
all docs

27  
docs citations

27  
times ranked

810  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. <i>Urology</i> , 2002, 60, 836-840.	0.5	118
2	TGF- $\beta$ 1/p53 signaling in renal fibrogenesis. <i>Cellular Signalling</i> , 2018, 43, 1-10.	1.7	110
3	Role of prostate biopsy schemes in accurate prediction of Gleason scores. <i>Urology</i> , 2006, 67, 379-383.	0.5	103
4	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016, 122, 702-711.	2.0	81
5	Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 263-273.	1.7	43
6	Management of urologic cancers during the pandemic and potential impact of treatment deferrals on outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 258-267.	0.8	13
7	Rationale and protocol for randomized study of transrectal and transperineal prostate biopsy efficacy and complications (ProBE-PC study). <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 688-696.	2.0	9
8	Genitourinary cancer management during a severe pandemic: Utility of rapid communication tools and evidence-based guidelines. <i>BJUI Compass</i> , 2020, 1, 45-59.	0.7	6
9	Impact of Enhanced Recovery after Surgery Protocols on Opioid Prescriptions at Discharge after Major Urological Cancer Surgery. <i>Urology Practice</i> , 2021, 8, 270-276.	0.2	5
10	Current and emerging trends in prostate cancer immunotherapy. <i>Asian Journal of Andrology</i> , 2019, 21, 6.	0.8	5
11	Interventions to Reduce Opioid Prescriptions following Urological Surgery: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 969-981.	0.2	5
12	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5027-5027.	0.8	3
13	Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder.. <i>Journal of Clinical Oncology</i> , 2017, 35, 350-350.	0.8	3
14	Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4522-4522.	0.8	2
15	Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection. <i>Asian Journal of Andrology</i> , 2015, 17, 864.	0.8	2
16	Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report. <i>Urology Case Reports</i> , 2021, 39, 101793.	0.1	1
17	Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate.. <i>Journal of Clinical Oncology</i> , 2016, 34, 187-187.	0.8	1
18	Prostate Biopsy Strategies: Current State of the Art. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 213-222.	2.3	0

#	ARTICLE	IF	CITATIONS
19	A rare case of urachal inflammatory myofibroblastic tumor. Urology Case Reports, 2021, 36, 101575.	0.1	0
20	Comprehensive genomic profiling of urothelial carcinoma of the kidney and ureter: Comparison with urothelial carcinoma of the bladder and impact on potential for targeted therapy selection.. Journal of Clinical Oncology, 2016, 34, 371-371.	0.8	0
21	Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer.. Journal of Clinical Oncology, 2017, 35, 429-429.	0.8	0
22	Validation of a new diagnostic platform for prostate cancer using expression profiling of small non-coding RNAs.. Journal of Clinical Oncology, 2018, 36, e24151-e24151.	0.8	0
23	Novel platform for monitoring bladder cancer recurrence using expression analysis of small non-coding RNAs.. Journal of Clinical Oncology, 2018, 36, 12070-12070.	0.8	0
24	Reply by Authors. Journal of Urology, 2022, 207, 981-981.	0.2	0